Fausto A. Rios Olais

Aza + venetoclax

Posters 6273 & 5109 tonight @ #ASH25 @ASH_hematology

ASH Plenary - IV Iron safe in infections! meetings-api.hematology.org/api/abstract/v…

Should we reexpose patients after asparaginase associated pancreatitis? 🤔🤔🤔

📊 How many patients with lymphoma or myeloma in the US actually benefit from bispecific antibodies? In our @BloodAdvances letter, we estimate eligibility and response under current FDA labels—and why real-world benefit may be limited. @THilalMD ashpublications.org/bloodadvances/…

🎯 Bottom line: Allo-HSCT offers curative potential in MDS/MPN overlap neoplasms. PTCy (± ATG) appears to improve survival outcomes without added relapse risk. 👉 Further multicenter studies needed. 📖 Full study: doi.org/10.1111/ejh.14… #HemeTwitter #AlloHSCT #GVHD

Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%. Read the full review “Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress” by Robin Foà, MD, from @sapienzaroma: nej.md/4mhBDvU

📝 A retrospective analysis published in Leukemia & Lymphoma found that the median OS was not reached in patients with Ph+ B-ALL receiving rituximab vs 14 months in those who did not. More news: lymphoblastic-hub.com #allsm #leusm #MedNews #MedEd

Thanks to all the professors and attendees who joined us at this first hematology congress at @incmnszmx @DrWendyStock @garciamanero @PratzKW @AlejandroLazo2 @RubenNiesvizky @GCC_Cortes @EnriqueSoto8 @CarmeloGurnari @Meyaix @patsnavarrete @VazyurVasquez @rajuan_27

@FernandoGLMD Esoooooo 🥹🥹🥹🙌🏻🙌🏻🙌🏻

📢 Body composition in adult ALL 📊 In our study published at @ESPENorg, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections. clinicalnutritionespen.com/article/S2405-… @RobertaDemiche3 @FernandoGLMD @analymorac @JessicaZaS

@mariempf @incmnszmx Felicidades Mariemcita!!!

R1 de Medicina Interna del @incmnszmx ❤️

🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉 Si tratas adultos con LLA en LATAM, te invitamos a participar completando nuestro formulario. 🔗 docs.google.com/forms/d/e/1FAI… Tu aporte será clave para mejorar la atención de LLA en la región.

@carmencrios Ando igual 🆘🆘🆘🆘

They not like us, they not like us, they not like us

El INCMNSZ felicita a la Dra. María Roberta Demichelis Gómez por su nombramiento como Jefa del Departamento de Hematología y Oncología.

1/ 📢 Let’s dive into a crucial topic in #Hematology: How do adult regimens compare with pediatric-inspired regimens (PIRs) for Philadelphia-negative ALL? Our study from Mexico offers some insights #ALL @RobertaDemiche3 @faustor @rajuan_27 @analymorac onlinelibrary.wiley.com/doi/10.1111/ej…

7/ Conclusions 🔹 Rituximab + TKIs may improve early responses and enhance survival in CD20+ Ph+ ALL without added toxicity. 🔹 These findings are critical for LMICs, where access to newer therapies is limited. 🔹 Future prospective trials are essential to confirm these results.

6/ Dose-dependent effects ✔️ Patients receiving >4 doses of rituximab had significantly better OS. •Median OS: Not reached (>4 doses) vs. 10 months (≤4 doses). •HR for mortality: 0.27 (p = .034). This aligns with prior data emphasizing the importance of adequate dosing.

4/ Results: Molecular Response Patients receiving rituximab achieved significantly higher 3-month MR4 rates: 🔹 Rituximab: 84% 🔹 No rituximab: 59% OR: 3.66 (p = .027) 3-month MR4 is critical, as it is linked to improved survival and lower relapse rates in some Ph+ ALL trials.